Novartis AG (NVS)

68.17
0.42 0.62
NYSE : Health Care
Prev Close 67.75
Open 67.66
Day Low/High 67.57 / 68.30
52 Wk Low/High 67.28 / 88.49
Volume 2.43M
Avg Volume 2.74M
Exchange NYSE
Shares Outstanding 2.38B
Market Cap 163.34B
EPS 7.40
P/E Ratio 18.58
Div & Yield 2.72 (4.00%)

Latest News

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

Wall Street scores a trifecta of record closes on Monday as a crude oil rally gives stocks an across-the-board boost.

Wall Street on Track for Across-the-Board Records as Crude Rallies

Wall Street on Track for Across-the-Board Records as Crude Rallies

Wall Street is on track for record closes for all the benchmark indices as crude oil resumes its rally.

Stocks Trade Near Records as Crude Oil Surge Plateaus

Stocks Trade Near Records as Crude Oil Surge Plateaus

Stocks are higher on Monday as an early-morning surge in crude oil prices plateaus around $47 a barrel.

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.

Stock Futures Edge Higher as Crude Surges on Hopes for OPEC Deal

Stock Futures Edge Higher as Crude Surges on Hopes for OPEC Deal

Stock futures edge higher on Monday morning as investors pin hopes on a production freeze agreement among major oil producers.

European Stocks Recover Gains as Energy Companies Pull Markets Higher

European Stocks Recover Gains as Energy Companies Pull Markets Higher

European stocks turned positive amid bullish oil sentiment ahead of November 30 OPEC meeting.

Novartis In Talks to Buy Generic Drug Maker

Novartis In Talks to Buy Generic Drug Maker

Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.

'Mad Money' Lightning Round: Target, Amazon, Tesla

'Mad Money' Lightning Round: Target, Amazon, Tesla

Jim Cramer says take a pass on TGT and the dollar stores; look at AMZN instead.

Jim Cramer's 'Mad Money' Recap: Ahead of Veterans Day, Cautious Optimism for Growth

Jim Cramer's 'Mad Money' Recap: Ahead of Veterans Day, Cautious Optimism for Growth

Jim Cramer honors veterans and those willing to invest in a brighter future for America.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.

GlaxoSmithKline Beats Estimates in Strong Third Quarter

GlaxoSmithKline Beats Estimates in Strong Third Quarter

Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.

European Stocks Mixed After Earnings Reports as Pound Plunges

European Stocks Mixed After Earnings Reports as Pound Plunges

The U.K. currency falls to its lowest intra-day level since the Oct. 7 'flash crash' before testimony from Bank of England Governor Mark Carney.

Earnings Reports Propel European Stocks Higher but AMS Plunges

Earnings Reports Propel European Stocks Higher but AMS Plunges

The chip maker sinks on news of production problems and a gloomy fourth-quarter prognosis.

Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts

Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts

The group's blood cancer drug Gleevec also holds up better than expected against generic competition.

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

Novartis May Be Too Generic

Novartis May Be Too Generic

Novartis stock has fallen 14% in the last year. A wave of generic drugs has wrecked results.

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.

Weak Start to Earnings Season, Crude Slump Pull Wall Street Into Selloff

Weak Start to Earnings Season, Crude Slump Pull Wall Street Into Selloff

Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.

Stocks at Three-Week Lows as Alcoa Heralds Poor Start to Earnings Season

Stocks at Three-Week Lows as Alcoa Heralds Poor Start to Earnings Season

Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Analyst Says Cooper is Poised to Gain Market Share

Analyst Says Cooper is Poised to Gain Market Share

A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.

Analysts' Actions -- Qualcomm, Walmart, Autozone and More

Analysts' Actions -- Qualcomm, Walmart, Autozone and More

Here are Friday's top research calls, including upgrades for Casey's and Qualcomm and downgrades for AutoZone and Mylan.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CPHD, KODK, PINC, SRLP Downgrades: APU, ATU, AZO, BDL, GATX, GRA, HLT, MYL, NVS, TI.A, VG Initiations: None Read on to get TheStreet Quant Ratings' detailed report: